ACG: No Cancer Risk With Biologic in Crohn’s (CME/CE)
WASHINGTON (MedPage Today) — Patients with Crohn’s disease who are taking infliximab don’t have a higher cancer rate than those on other therapies, a researcher said here.
Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com